{"id":574,"date":"2009-07-07T10:42:11","date_gmt":"2009-07-07T06:42:11","guid":{"rendered":"http:\/\/solopov.ru\/?p=574"},"modified":"2009-07-07T10:42:11","modified_gmt":"2009-07-07T06:42:11","slug":"adrenomimetic-drugs-new-diagnostic-and-therapeutic-aspects-in-bronchial-asthma","status":"publish","type":"post","link":"https:\/\/solopov.ru\/adrenomimetic-drugs-new-diagnostic-and-therapeutic-aspects-in-bronchial-asthma\/","title":{"rendered":"Adrenomimetic drugs: new diagnostic and therapeutic aspects in bronchial asthma"},"content":{"rendered":"
ADRENOMIMETIC DRUGS: NEW DIAGNOSTIC AND THERAPEUTIC ASPECTS IN BRONCHIAL ASTHMA<\/p>\n
V. N. Solopov, I. V. Lunichkina<\/p>\n
Summary<\/p>\n
It is suggested to use alfa-stimulating effect of naphthyzine and halazoline for pharmacological spirometric testing in evaluating the inflammatory-edematous componert of bronchial obstruction. Those antiedemics combined with standard bronchospasmolytics (beta-2-agonists and cholinolytics) proved effective in arresting episodes of asphyxia. Optimal doses of naphthyzine and halazoline, related side effects have been clarified in case of their addition to selective beta-2-agonists, cholinolytics and combinations thereof. In contrast to nonselective adrenomimetic drugs adrenaline and ephedrine, naphthyzine, halazoline or similar medicines do not produce cardiostimulation this justifying their use in combination with selective bronchospasmolytic berotec, salbutamole, berodual and atrovent.<\/p>\n
\u00abKlin. Med\u00bb (Msk) 1991, \u21162, \u0441. 55-58<\/p>\n","protected":false},"excerpt":{"rendered":"
ADRENOMIMETIC DRUGS: NEW DIAGNOSTIC AND THERAPEUTIC ASPECTS IN BRONCHIAL ASTHMA V. N. Solopov, I. V. Lunichkina Summary It is suggested to use alfa-stimulating effect of naphthyzine and halazoline for pharmacological spirometric testing in evaluating the inflammatory-edematous componert of bronchial obstruction. Those antiedemics combined with standard … <\/p>\n